Fund chief to kickstart fundamental changes in antibiotics market
Even though Novo Nordisk-funded AMR Action Fund was created to finance the development of antibiotics, CEO Henry Skinner expects that a lot of the fund's work will also involve raising awareness on the deepening lack of new antibiotics.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Henry Skinner struggles to hold himself back when discussing current issues with the antibiotics market. As the newly appointed CEO for the antimicrobial resistance research fund AMR Action Fund, being passionate about this area is sort of embedded in his job description.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Global antimicrobial fund expands with USD 140m and CEO
For subscribers
